China Pharma Holdings (CPHI) Non-Current Deferred Tax Liability (2010 - 2026)

China Pharma Holdings' Non-Current Deferred Tax Liability history runs 17 years deep, the most recent figure standing at $759628.0 for Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 3.74% year-over-year to $759628.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $759628.0 (up 3.74% YoY) and the FY2025 annual result came in at $747805.0, up 2.27% from the prior year.
• Non-Current Deferred Tax Liability was $759628.0 for Q1 2026 at China Pharma Holdings, up from $747805.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $827978.0 in Q1 2022 and bottomed at $727417.0 in Q2 2023.
• A 5-year average of $749763.4 and a median of $740828.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability slipped 8.65% — and 2026, when it grew 3.74%.
• China Pharma Holdings' Non-Current Deferred Tax Liability stood at $754698.0 in 2022, then dropped by 1.67% to $742114.0 in 2023, then decreased by 1.47% to $731202.0 in 2024, then rose by 2.27% to $747805.0 in 2025, then climbed by 1.58% to $759628.0 in 2026.
• Business Quant data shows CPHI's Non-Current Deferred Tax Liability at $759628.0 in Q1 2026, $747805.0 in Q4 2025, and $739733.0 in Q3 2025.